NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

血癌治療藥的全球市場 (到2027年) - 上市產品、開發中產品,機會,課題,市場規模,主要企業

Global Hematological Cancer (Blood Cancer) Therapy Market to 2027 - Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players

出版商 GlobalData 商品編碼 1023478
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
血癌治療藥的全球市場 (到2027年) - 上市產品、開發中產品,機會,課題,市場規模,主要企業 Global Hematological Cancer (Blood Cancer) Therapy Market to 2027 - Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players
出版日期: 2021年08月31日內容資訊: 英文 125 Pages
簡介

血癌,包括100多種不同的腫瘤,這些腫瘤由血液、骨髓或淋巴結細胞的異常增殖或分化引起。近年來,更多靶向療法的出現使化學療法發生了轉變,在某些情況下轉向了更加個性化的方法。細胞療法在治療血液癌症方面處於領先地位,現在有幾種此類療法可用於多種適應症。預計仿製藥的使用在不久的將來會下降,而靶向、個性化治療的使用預計會增加。成長的主要驅動力包括預期批准和推出包含多種治療方式的多種管道療法,預計到2027年,細胞療法的成長增幅最大。

本報告提供全球血癌治療藥市場相關調查分析,主要趨勢,臨床試驗,上市產品、開發中產品,市場分析與預測,未滿足需求,主要企業等相關的系統性資訊。

目錄

目錄

第1章 序文

第2章 摘要整理

第3章 血癌概要

  • 所謂血癌
  • 血癌的治療管理
  • 主要8個國家的血癌治療的重要里程碑

第4章 趨勢

  • 產業趨勢

第5章 價值鏈

  • 血癌的價值鏈
  • 抗體
  • 細胞治療
  • 化療
  • 其他MOA
  • 標靶治療

第6章 臨床試驗

  • 血癌的臨床試驗
  • 血癌的進行中的臨床試驗
  • 血癌的進行中的臨床試驗:各地區
  • 血癌的進行中的臨床試驗:各主要贊助商
  • 血癌的臨床試驗:課題
  • 血癌的臨床試驗:機會

第7章 上市產品

  • 全球已上市血癌產品
  • 主要8個國家的已上市血癌產品
  • 血癌的整體市場規模
  • 全球主要抗體治療
  • 全球主要細胞治療
  • 全球主要化療治療
  • 全球主要及其他的MOA治療
  • 全球主要標靶治療治療

第8章 開發中產品

  • 全球血癌開發中產品
  • 全球血癌開發平台:抗體
  • 全球血癌開發平台:細胞治療
  • 全球血癌開發平台:化療
  • 全球血癌開發平台:其他MOA
  • 全球血癌開發平台:標靶治療

第9章 市場分析

  • 市場分析與預測:抗體
  • 市場分析與預測:細胞治療
  • 市場分析與預測:化療
  • 市場分析與預測:其他MOA
  • 市場分析與預測:標靶治療
  • 2017年以後在血癌領域完成的交易前10名
  • 血癌領域的最新的交易
  • M&A:血癌 (2020年下半年∼2021年前半期)
  • M&A:血癌 (2020年下半年)

第10章 企業

  • BMS
  • Johnson & Johnson/Janssen
  • Novartis
  • Pfizer
  • Roche

第11章 機會及未滿足需求

  • 全球血癌:機會
  • 全球血癌:課題
  • 血癌的未滿足需求:差距分析

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCHT287

Hematological cancers, often referred to as blood cancers, encompass over 100 diverse neoplasms that arise from the abnormal proliferation or differentiation of cells of the blood, bone marrow, or lymph nodes. Hematological cancers accounted for almost 10% of new cancer diagnoses in the US in 2020. A diverse array of drugs are used in the treatment of hematological cancers. Historically, chemotherapies were an important part of the treatment paradigm for many indications. The emergence of more targeted therapies in recent years has seen a shift away from chemotherapy, in some cases towards a more personalized approach. The use of cell therapies has been pioneered in the treatment of hematological cancers and several such therapies are now available for multiple indications.

The hematological cancer therapy market is diverse and highly genericized. Targeted therapies are currently the most valuable segment within the hematological cancer market, accounting for $39.9B worth of sales in 2020. Use of generic chemotherapies is expected to fall in the near future, while the use of targeted, personalized therapies is expected to increase.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of multiple pipeline therapies encompassing a wide range of therapeutic modalities, with cell therapies expected to see the greatest increase in growth to 2027.
  • Targeted therapies currently account for the highest proportion of sales, followed by antibodies. Together, these therapeutics have accounted for over 90% of sales since 2016.
  • Indication-specific differences means some patients have access to multiple therapy types, while others are underserved. The degree of pipeline innovation is highly variable between indications.
  • The most important unmet needs in the hematological cancer market include: the need for greater therapeutic options for relapsed/refractory patients across multiple indications, the need to better understand the most effective sequencing of treatments, the need for greater therapeutic options for high-risk patients and the need to reduce the increasingly high cost of therapy.

Key Questions Answered

  • What are the main trends in the treatment of hematological cancers today?
  • What is the status of clinical trials in hematological cancers? Which indications have the greatest number of late-stage trials and who are the most active sponsors of clinical trials in hematological cancers?
  • How does the market in branded therapies look in terms of therapy types? Which indications have the greatest number of marketed products? What are the top selling treatments globally?
  • How many and what types of therapies are currently in development? Which targets are most heavily investigated? Which indications have strong pipelines and which are lacking in diversity?
  • What are the current unmet needs across hematological cancers? What the opportunities for developers in this setting and what are the main challenges?

Scope

  • Overview of hematological cancers including classification and treatment management, and important milestones in the treatment of hematological cancers in the 8MM.
  • Global trends in the hematological cancer market, including the impact of cell therapies on the market and how their use is expected to evolve, and how the increased understanding of the molecular basis of disease is influencing treatment, diagnosis and prognosis across different hematological cancer indications.
  • Key topics covered include ongoing clinical trials, top selling agents from each treatment type, pipeline therapies, market analysis by treatment type, overview of noteworthy deals, and unmet needs and opportunities.
  • Pipeline analysis: Overview of pipeline products globally and in the 8MM, including breakdown by treatment type and split across different phases, analysis of highly investigated targets, overview of pipeline products by indication, phase and treatment type.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global hematological cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hematological cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global hematological cancer therapeutics market from 2020-2027.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

  • 1.1. Table of Contents
  • 1.2. Abbreviations
  • 1.3. Related Reports

2. Executive Summary

  • 2.1. Key Findings

3. Hematological Cancer Overview

  • 3.1. What Are Hematological Cancers?
  • 3.2. Treatment Management for Hematological Cancers
  • 3.3. Important Milestones in the Treatment of Hematological Cancers in the 8MM

4. Trends

  • 4.1. Industry Trends

5. Value Chain

  • 5.1. Hematological Cancers Value Chain
  • 5.2. Antibodies
  • 5.3. Cell Therapies
  • 5.4. Chemotherapies
  • 5.5. Other MOAs
  • 5.6. Targeted Therapies

6. Clinical Trials

  • 6.1. Clinical Trials for Hematological Cancers
  • 6.2. Ongoing Clinical Trials for Hematological Cancers
  • 6.3. Ongoing Clinical Trials for Hematological Cancers by Region
  • 6.4. Ongoing Clinical Trials in Hematological Cancers by Leading Sponsors
  • 6.5. Clinical Trials in Hematological Cancers - Challenges
  • 6.6. Clinical Trials in Hematological Cancers - Opportunities

7. Marketed Products

  • 7.1. Hematological Cancers Marketed Products Globally
  • 7.2. Hematological Cancers Marketed Products in the 8MM
  • 7.3. Total Market Size for Hematological Cancers
  • 7.4. Leading Antibody Treatments Globally
  • 7.5. Leading Cell Therapy Treatments Globally
  • 7.6. Leading Chemotherapy Treatments Globally
  • 7.7. Leading Treatments with Other MOAs Globally
  • 7.8. Leading Targeted Therapy Treatments Globally

8. Pipeline Products

  • 8.1. Global Hematological Cancer Pipeline Products
  • 8.2. Global Hematological Cancer Pipeline - Antibodies
  • 8.3. Global Hematological Cancer Pipeline - Cell Therapies
  • 8.4. Global Hematological Cancer Pipeline - Chemotherapies
  • 8.5. Global Hematological Cancer Pipeline - Other MOAs
  • 8.6. Global Hematological Cancer Pipeline - Targeted Therapies

9. Market Analysis

  • 9.1. Market Analysis and Forecast - Antibodies
  • 9.2. Market Analysis and Forecast - Cell Therapies
  • 9.3. Market Analysis and Forecast - Chemotherapies
  • 9.4. Market Analysis and Forecast - Other MOAs
  • 9.5. Market Analysis and Forecast - Targeted Therapies
  • 9.6. Top 10 Completed Deals in the Hematological Cancer Space Since 2017
  • 9.7. Latest Deals in the Hematological Cancer Space
  • 9.8. Mergers and Acquisitions Hematological Cancer - H2 2020-H1 2021
  • 9.9. Mergers and Acquisitions Hematological Cancer - H2 2020

10. Companies

  • 10.1. BMS
  • 10.2. Johnson & Johnson/Janssen
  • 10.3. Novartis
  • 10.4. Pfizer
  • 10.5. Roche

11. Opportunities and Unmet Needs

  • 11.1. Global Hematological Cancers - Opportunities
  • 11.2. Global Hematological Cancers - Challenges
  • 11.3. Unmet Needs in Hematological Cancers - Gap Analysis

12. Appendix

  • 12.1. Bibliography
  • 12.2. Primary Research
  • 12.3. About the Authors
  • 12.4. About GlobalData
  • 12.5. Contact Us
  • 12.6. Disclaimer